Chennai-based Lamark Biotech has secured ₹6.5 crore in seed funding to scale its ProteoStrong platform, which enables room-temperature storage of biologics like insulin. The funds will boost R&D, GMP-scale production, and global filings. With a focus on accessibility and affordability, Lamark aims to revolutionise drug delivery in rural India and emerging markets lacking cold-chain infrastructure.